Women of childbearing potential must as mentioned in the summary of product characteristics (SPC) using two effective methods of contraception during treatment, and men whose partner is of childbearing potential must use effective contraception during treatment. For all patients treated men and women, contraception should be continued during the four months following the discontinuation of nivolumab.
You may not be if
development of haematological tumor during treatment
Patients requiring concomitant chronic treatment with systemic corticosteroids or other immunosuppressive agents
Patients with autoimmune disease.
Patient with Occular melanoma
Clareo Health | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
